Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Cyteir Therapeutics, Inc. CYT
$2.16
-$0.01 (-0.69%)
На 18:04, 12 мая 2023
-7.41%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
76641050.00000000
-
week52high
4.22
-
week52low
1.13
-
Revenue
0
-
P/E TTM
-2
-
Beta
0.00000000
-
EPS
-1.32000000
-
Last Dividend
0.00000000
-
Next Earnings Date
16 мар 2022 г. в 10:59
Описание компании
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Wedbush | Outperform | Outperform | 17 мар 2022 г. |
| Northland Capital Markets | Outperform | 07 февр 2022 г. | |
| Wedbush | Outperform | 13 июл 2021 г. | |
| Morgan Stanley | Overweight | 13 июл 2021 г. | |
| JP Morgan | Overweight | 13 июл 2021 г. | |
| Morgan Stanley | Equal-Weight | Overweight | 09 сент 2022 г. |
| JP Morgan | Neutral | Overweight | 20 янв 2023 г. |
| Morgan Stanley | Underweight | Equal-Weight | 03 февр 2023 г. |
| B of A Securities | Neutral | Buy | 30 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| RENSCHLER MARKUS MD | D | 32973 | 30437 | 21 дек 2022 г. |
| RENSCHLER MARKUS MD | D | 0 | 106345 | 21 дек 2022 г. |
| RENSCHLER MARKUS MD | A | 978736 | 30437 | 21 дек 2022 г. |
| RENSCHLER MARKUS MD | A | 948299 | 106345 | 21 дек 2022 г. |
| Zakrzewski Joseph S | A | 154618 | 21202 | 07 дек 2022 г. |
| Novo Holdings A/S | D | 3940413 | 900000 | 20 июл 2022 г. |
| Zakrzewski Joseph S | A | 133416 | 743 | 12 мая 2022 г. |
| Zakrzewski Joseph S | A | 132673 | 1000 | 11 мая 2022 г. |
| THERO JOHN F | A | 10000 | 10000 | 10 мая 2022 г. |
| Zakrzewski Joseph S | A | 131673 | 49406 | 10 мая 2022 г. |
Новостная лента
Cyteir Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
Business Wire
31 авг 2022 г. в 07:30
LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced that its President and Chief Executive Officer, Markus Renschler, MD, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 14, 2022. Morgan Stanley 20th Annual Global Healthcare Conference Date: Wednesday, September 14 Time: